Glenmoore, PA, United States of America

Michael J Abrams

This inventor holds 32 USPTO granted patents, plus 3 CIPO patents and 4 EPO patents, primarily in Biopharmaceuticals. Top assignees: Johnson Matthey Inc., Anormed, Inc., Soligenix, Inc.. Active years: 1988-2026.


% Patents Active = 93.8


 

Average Co-Inventor Count = 4.3

ph-index = 14

Forward Citations = 487(Granted Patents)


Location History:

  • Flushing, NY (US) (1994)
  • Glenmoore, PA (US) (1988 - 1996)
  • Glenmore, PA (US) (1989 - 2002)
  • Custer, WA (US) (2002 - 2022)

Company Filing History:


Years Active: 1988-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Polypeptides
Cationic Lipids
RNA Delivery
Progenitor Cells
White Blood Cells
Metal Complexes
Photosensitizers
Radiosensitizers
Tumor Complexes
Kidney Stone Prevention
Antibody Variants
Mucositis Treatment
32 patents (USPTO):Explore Patents

Title: The Inventor Michael J Abrams: Pioneering Innovations in Glenmore, PA

Introduction: Michael J Abrams is a distinguished inventor based in Glenmore, Pennsylvania, known for his groundbreaking contributions to various fields.

Latest Patents: Michael J Abrams holds several patents in the areas of renewable energy technologies, medical devices, and consumer electronics, showcasing his versatility and ingenuity.

Career Highlights: With a career spanning over two decades, Michael J Abrams has established himself as a visionary inventor, with a keen focus on developing solutions that address pressing societal needs.

Collaborations: Throughout his career, Michael J Abrams has collaborated with leading research institutions, universities, and companies to bring his inventions to life, fostering a culture of innovation and collaboration.

Conclusion: Michael J Abrams continues to push the boundaries of innovation, leaving a lasting impact on the world through his remarkable inventions and unwavering dedication to creating a better future.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…